載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.9788
+US$0.0057 · +0.59%
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
前收盤價
US$0.9788
+US$0.0057 · +0.59%
盤中時間採用ET。市場資料可能有所延遲。
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
日內區間
目前US$0.9788
52週區間
目前US$0.9788
盤中時間採用ET。市場資料可能有所延遲。
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
日內區間
目前US$0.9788
52週區間
目前US$0.9788
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 461.8萬 USD | 364.3萬 USD | 633.2萬 USD | 701.2萬 USD | 888.6萬 USD |
| 毛利 | −461.8萬 USD | −364.3萬 USD | −633.2萬 USD | −701.2萬 USD | −888.6萬 USD |
| 研究與開發 | 461.8萬 USD | 364.3萬 USD | 633.2萬 USD | 701.2萬 USD | 888.6萬 USD |
| 銷售、一般及管理費用 | 460.2萬 USD | 374.4萬 USD | 428.8萬 USD | 445萬 USD | 462.5萬 USD |
| 營業費用 | 460.2萬 USD | 374.4萬 USD | 449.2萬 USD | 445萬 USD | 462.5萬 USD |
| 利息收入 | — | 23.1萬 USD | — | — | — |
| 折舊和攤銷 | 3000 USD | 3.5萬 USD | 18.4萬 USD | 19.3萬 USD | 7.5萬 USD |
| 營業利益 | −922萬 USD | −738.7萬 USD | −1082.4萬 USD | −1146.2萬 USD | −1351.1萬 USD |
| 淨利 | −869.8萬 USD | −715萬 USD | −1082.6萬 USD | −1148萬 USD | −1328.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
